Drug GHL 901
 |
Erectile dysfunction is a physical condition that affects 10% of men worldwide. The current treatment is the use of drugs that prevent the enzyme 5-phosphodiesterase. Most notable products of this class are Viagra (TM), Cialis (TM), and Levitra(TM), collectively generate over $3 billion annually.. All of them carry a considerable side effects due to gasteric and colonic absorption, these include acidoses(gas build up), stol run, and many more. New formulation of these products are developed by us which bypassess all the gasterointestinal side effects, making the drug far more patient friendly and desirable. |
Drug GHL 902
 |
Addiction to alcohol, tobacco and controlled substances are a major social and health care problem. More than $10 Billion is spent on addiction and addictive products. A never ending growing market. From developing to developed countries, we all face a mountain of social and economic problem. The world is seeking a solution to curb the growth of this industry. We are on the forefront of this issue by bringing new technology to curb the addiction and its growth through society |
Drug GHL 903
 |
Obesity is a big problem. It is estimated that 20% of American to be obese and another 40% are overweight. Beside the exercise, many different food formulation, herbal products and pharmaceutical products are being used to help reduce the appetite, and weight. While the anti-obesity market for products and process are estimated at $5 billion, very little success has been reported. Most people going through the severe forms of exercise and diet, etc, they regain their weight within few months of stopping their diet program The vicious cycle of loose and gain has tired most people. It is highly desirable to have a system that once the body has lost considerable weight, it can stay lean for long time. New drugs are developed which will exactly do that. Once a person gone through the execise and diet and lost weight, by using the drug, he/she may be able to manage to maintain the weght loss as the drug fight strongly against the appetite. |
LATEST MEDICAL NEWS
| Technique That Could Resolve The Problem Of Fake Medicines In Developing Countries |
|
Counterfeiting of drugs is a huge industry with an annual turnover of more than SEK 500 billion. In Africa the situation is extremely serious. Half of the malaria medication sold there could be ineffective or even harmful. Researchers from Lund and the UK have now developed a technique that could resolve the situation. In two years the researchers hope to have a prototype ready...
|
| Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupropion SR) |
|
Contrave (naltrexone SR/bupropion SR), an investigational drug aimed at combination therapy to address both biological and behavioral drivers of obesity, will be developed and commercialized by Orexigen Therapeutics, Inc. and Takeda Pharmaceutical Company Limited in the USA, Canada and Mexico. The two drug firms have just signed an exclusive partnership for the North American area...
|
•Sublingual Drug (GHL901)
•Rapid onset of action (approx. 5 min and lasting 4 hours), reaching blood within 2 minutes
•No stomach or guts exposure, no gastrointestinal side effects (acidosis, stomach gas build-up, diarrheal)
•Affordable, lower cost.
•Sublingual Drug (GHL902)
•Anti addiction product
•Rapid blood absorbtion
•Rapid action against addiction
•Patient friendly and economical
•Sublingual Drug (GHL903)
•Needle free, easily administered, minimal requirement
•Over the Counter (reduced need for prescriptions)
•Economical, mass distribution, highly affordable